DR REDDYS LABORATORIES LTD Q3 RESULTS
F&O outliers: September seasonality weighs on ICICI Bank, Adani Ports, TVS Motors, 7 others. Here's why
Over the last decade, five F&O stocks showed positive seasonality in September with average returns over 5%, including TVS Motor, Deepak Nitrite, Abbott India, Escorts Kubota, and Zee Entertainment. Conversely, ICICI Bank, APSEZ, SBI, Cummins India, and Dabur India had negative seasonality, with average losses of 2% or more.
Buy Dr. Reddy's Laboratories, target price Rs 8010: JM Financial
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 116021.72 Crore) operating in Pharmaceuticals sector.
Market Wrap: Sensex gains 148 points, Nifty above 24,800 on positive global cues, Fed minutes
The Fed minutes confirmed expectations of a rate cut next month, with most policymakers agreeing it would be appropriate if data aligns with forecasts. Market participants are now focused on US initial jobless claims at 6:00 pm IST and Fed Chair Jerome Powell's upcoming remarks at the Jackson Hole Economic Symposium.
Dr Reddy's Laboratories, TCS top stocks to buy post June quarter results: Siddhartha Khemka
The 1QFY25 corporate earnings report revealed both growth and challenges in India’s market. The Nifty50’s earnings rose 4% YoY, aided by companies like HDFC Bank and Tata Motors, despite setbacks from Oil Marketing Companies. The auto sector displayed strong volume growth, while IT services and healthcare sectors met expectations with promising future outlooks.
Nifty's 4% YoY Q1 PAT growth surpasses Motilal's estimates. Adani Ports and four others see FY25 earnings upgrades
Nifty achieved a 4% YoY growth in profit after tax (PAT), exceeding Motilal Oswal's 3% estimate, though it's the slowest growth since the pandemic quarter of 2020. Key contributors to this growth were HDFC Bank, Tata Motors, ICICI Bank, Maruti Suzuki, and Tata Consultancy Services (TCS), which together accounted for 127% of the incremental YoY earnings.
Apollo 24/7 GMV to go up to Rs 1,000 cr per quarter over next 18 months: Suneeta Reddy
Apollo Hospitals' Suneeta Reddy forecasted a 5% price impact for next quarter, citing the recent muted performance from elections and a heatwave. Regional occupancy and margins varied, with Nashik serving as a referral center. Apollo 24/7 aims for Rs 1,000 crore quarterly in six quarters. AHLL is on an improving revenue trajectory despite new centers impacting margins.
- Go To Page 1
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
Dr Lal PathLabs Q1 Results: Profit rises 28% to Rs 106 crore on strong testing demand, beats estimates
Consolidated net profit rose 28% to 1.06 billion rupees (around $13 million) for the quarter ended June 30, beating analysts' estimate of 992.7 million rupees, per LSEG.
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
D-St cheers Fed's dovish tone: Nifty surges past 25K milestone, Sensex sets new record
On Wednesday, the US Federal Reserve maintained its key interest rate at 5.25–5.5% for the eighth consecutive time, as expected, while signaling the possibility of a rate cut in its next meeting in September. From the Nifty stocks, Power Grid Corporation, Coal India, ONGC, HDFC Bank, and Dr Reddy's Laboratories were the top gainers, rising 2-4%. On the other hand, M&M, Tata Steel, Hero MotoCorp, Britannia, and Tata Motors ended with cuts.
Stocks in news: ICICI Bank, Adani Wilmar, ACC, Dr Reddy's, IndiGo, IndusInd Bank
Bandhan Bank on Friday reported 47% growth in its consolidated net profit at Rs 1,063 crore in the first quarter, compared with Rs 721 crore in the last year period.
Dr Reddy’s Laboratories board announces 1:5 stock split
Additionally the company has also announced that each American Depositary Share (ADS) will still represent 1 equity share. As a result, the number of ADSs held by each American Depositary Receipt holder will increase in proportion to the increase in equity shares.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Q1 results today: ICICI Bank, Dr Reddy's among 34 companies to announce earnings on Saturday
Finolex Industries, IEC Education, IFB Industries, J&K Bank, Jaiprakash Power, SBFC Finance, Vishal Fabrics, Spandana Sphoorty, Smruthi Organics, NTPC, Genus Power, Gujarat Cotex among others will also declare their June quarter results.
Dr Reddy's Q1 Preview: PAT may fall 4% YoY on pricing pressure, subdued US sales
In the preceding March quarter, Dr Reddy's reported a consolidated net profit growth of 36% year-on-year to Rs 1,307 crore, while revenue from operations rose 12% year-on-year to Rs 7,083 crore.
Budget 2024, Q1 earnings action among 11 factors to impact D-Street mood this week
The short-term trend of Nifty seems to have reversed from all-time highs, Nagaraj Shetti of HDFC Securities said. The formation of candle patterns as per daily and weekly charts indicate the possibility of more weakness in the market ahead, he warned.
CDSL, and Nestle among 16 stocks trading ex-dividend from Tuesday. Last chance to buy!
Dividends are distributed to shareholders listed in the company's database on the record date. With the T+1 settlement framework, the record date and ex-date align in most cases, except when a market holiday follows the ex-date.
Banking stocks lift Sensex, Nifty to new heights in July opening
D-Sreet closed on a positive note on Monday, with the S&P BSE Sensex gaining 443.46 points to settle at 79,476.19. The broader Nifty index also rose, adding 131.35 points to close at 24,141.95. The banking sector showed particular strength, with the banking gauge up by 0.44%. Tech Mahindra, Wipro, Bajaj Finance, Grasim Industries, and UltraTech Cement were among the top gainers, while NTPC, Eicher Motors, Apollo Hospitals Enterprise, SBI, and Dr. Reddy's Laboratories experienced declines. Market capitalisation of all the BSE listed companies increased by Rs 344,798 crore.
Dr Reddy's to buy nicotine replacement brands from UK-based Haleon for $632 million
The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the US.
Move over PSUs, defensive bets can be the next big story under Modi 3.0
Defensive sectors like FMCG and pharma are emerging as potential winners under Modi 3.0, with experts forecasting gains fueled by rural push and policy actions. Investors are advised to explore stocks like HUL, Dabur, and pharma majors for potential returns amidst PSU valuation concerns.
Apollo Hospitals Q4 Results: Net profit soars 77% YoY to Rs 258 crore; revenue jumps 15%
Apollo Hospitals Q4 Results: Revenue from operations for the January-March 2024 period increased 15% YoY to Rs 4,944 crore. The company's board has recommended a final dividend of Rs 10 per share for FY24. EBITDA for the fourth quarter stood at Rs 640 crore in the reporting March quarter, compared with Rs 488 crore in the same quarter a year earlier.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Results: Net profit jumps 36% YoY to Rs 1307 crore
Dr Reddy's has reported a 36% year-on-year jump in quarterly net profit, helped by increase in volumes of base business, new product launches, partially offset by price erosion in certain markets.
Q4 results today: PB Fintech, Dr Reddy's among 43 companies to announce results
Q4 results today: 43 companies are set to announce Q4 results, with Dr Reddy's and PB Fintech in focus. Dr Reddy's eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Load More
